{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:33:52Z","timestamp":1787826832608,"version":"build-2784847793"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"name":"Fondo de Investigaci\u00f3n Sanitaria-Fondos FEDER"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"DOI":"10.1093\/jac\/dkx090","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T12:12:24Z","timestamp":1488456744000},"page":"2083-2088","source":"Crossref","is-referenced-by-count":28,"title":["Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response"],"prefix":"10.1093","volume":"72","author":[{"given":"Silvia","family":"Requena","sequence":"first","affiliation":[{"name":"Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Trevi\u00f1o","sequence":"additional","affiliation":[{"name":"Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Cabezas","sequence":"additional","affiliation":[{"name":"Hospital de Poniente, Almer\u00eda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Garcia-Delgado","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Amengual","sequence":"additional","affiliation":[{"name":"Corporaci\u00f3n Sanitaria Parc Taul\u00ed, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Lozano","sequence":"additional","affiliation":[{"name":"Hospital de Poniente, Almer\u00eda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Pe\u00f1aranda","sequence":"additional","affiliation":[{"name":"Son Espases Hospital, Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Hospital de Poniente, Almer\u00eda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Soriano","sequence":"additional","affiliation":[{"name":"La Paz University Hospital & Autonomous University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"de Mendoza","sequence":"additional","affiliation":[{"name":"Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Spanish HIV-2 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"key":"key\n\t\t\t\t20180328172517_dkx090-B1","first-page":"44","article-title":"HIV interaction with human host: HIV-2 as a model of a less virulent infection","volume":"18","author":"Azevedo-Pereira","year":"2016","journal-title":"AIDS Rev"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000319929","article-title":"Epidemiology and seroprevalence of human immunodeficiency virus type 2","volume":"54","author":"Kashyap","year":"2011","journal-title":"Intervirology"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/COH.0000000000000299","article-title":"Mortality and survival patterns of people living with HIV-2","volume":"11","author":"Tchounga","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B4","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B5","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1073\/pnas.222366699","article-title":"Structure of HIV-2 reverse transcriptase at 2.35-\u00c5 resolution and the mechanism of resistance to non-nucleoside inhibitors","volume":"99","author":"Ren","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B6","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.3390\/v7122931","article-title":"Inhibition profiling of retroviral protease inhibitors using an HIV-2 modular system","volume":"7","author":"Mahdi","year":"2015","journal-title":"Viruses"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B7","doi-asserted-by":"crossref","first-page":"20044","DOI":"10.7448\/IAS.19.1.20044","article-title":"Immunologic response in treatment-na\u00efve HIV-2-infected patients: the IeDEA West Africa cohort","volume":"19","author":"Balestre","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B8","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/jac\/dkr164","article-title":"Drug resistance mutations in patients infected with HIV-2 living in Spain","volume":"66","author":"Trevi\u00f1o","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B9","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/civ572","article-title":"HIV-2EU-supporting standardized HIV-2 drug resistance interpretation in Europe: an update","volume":"61","author":"Charpentier","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B10","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/QAD.0b013e32833f9e36","article-title":"In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S\/GSK1349572","volume":"24","author":"Charpentier","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B11","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","article-title":"HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro","volume":"62","author":"Roquebert","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcv.2015.01.001","article-title":"Dolutegravir for the treatment of HIV-2 infection","volume":"64","author":"Trevi\u00f1o","year":"2015","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2013.12.001","article-title":"Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection","volume":"102","author":"Men\u00e9ndez-Arias","year":"2014","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B14","first-page":"212","article-title":"The burden of neglected HIV-2 and HTLV-1 infections in Spain","volume":"17","author":"Trevi\u00f1o","year":"2015","journal-title":"AIDS Rev"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jviromet.2006.02.005","article-title":"Development and evaluation of a real-time RT-PCR assay for quantification of cell-free human immunodeficiency virus type 2 using a Brome Mosaic Virus internal control","volume":"135","author":"Ferns","year":"2006","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B16","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B17","first-page":"132","article-title":"2015 update of the drug resistance mutations in HIV-1","volume":"23","author":"Wensing","year":"2015","journal-title":"Top Antivir Ther"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drug over the past 50 years","volume":"29","author":"Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B19","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/cir510","article-title":"Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK","volume":"53","author":"Rockstroh","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B21","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","article-title":"Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV","volume":"3","author":"Dow","year":"2014","journal-title":"Infect Dis Ther"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir resistant HIV-1 infection: 24-week results of the VIKING study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral experienced patients with raltegravir and\/or elvitegravir resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B25","doi-asserted-by":"crossref","first-page":"e45372","DOI":"10.1371\/journal.pone.0045372","article-title":"Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens","volume":"7","author":"Smith","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B26","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1128\/AAC.00405-13","article-title":"Complex patterns of protease inhibitor resistance among antiretroviral treatment experienced HIV-2 patients from Senegal: implications for second-line therapy","volume":"57","author":"Raugi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B27","doi-asserted-by":"crossref","first-page":"e92747","DOI":"10.1371\/journal.pone.0092747","article-title":"HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen","volume":"9","author":"Cavaco-Silva","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B28","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/AAC.00984-08","article-title":"Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase","volume":"53","author":"Jones","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jcv.2009.06.020","article-title":"Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity","volume":"46","author":"Salgado","year":"2009","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12977-015-0146-8","article-title":"In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2","volume":"12","author":"Smith","year":"2015","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B31","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.antiviral.2011.12.008","article-title":"In vitro resistance selection using elvitegravir, raltegravir and two metabolites of elvitegravir M1 and M4","volume":"93","author":"Margot","year":"2012","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B33","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/cid\/civ124","article-title":"Dolutegravir in HIV-2 infected patients with resistant virus to first-line integrase inhibitors from the French named patient program","volume":"60","author":"Descamps","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B34","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1128\/JVI.06618-11","article-title":"Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo","volume":"86","author":"Fransen","year":"2012","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QCO.0b013e32835ba81c","article-title":"Evolution of HIV integrase resistance mutations","volume":"26","author":"Quashie","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B36","doi-asserted-by":"crossref","first-page":"9683","DOI":"10.1128\/JVI.00947-14","article-title":"Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors","volume":"88","author":"Hassounah","year":"2014","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B37","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1093\/jac\/dku095","article-title":"New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors","volume":"69","author":"Malet","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dku474","article-title":"G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance","volume":"70","author":"Munir","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328172517_dkx090-B39","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/jac\/dkw071","article-title":"Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors","volume":"71","author":"Brenner","year":"2016","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/7\/2083\/17723471\/dkx090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T23:10:55Z","timestamp":1750029055000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/72\/7\/2083\/3078891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,3,23]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx090","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,3,23]]}}}